{"product_id":"insmed-ansoff-matrix","title":"Insmed Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Insmed Amsoff Matrix Analysis gives a clear, company-specific view of growth options across market penetration, market development, product development, and diversification. What you see on this page is a real preview of the actual analysis, not just marketing text, so you can review the style and substance before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARIKAYCE: 3 major geographies, 1 core niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed is still driving ARIKAYCE penetration in refractory MAC lung disease, where it already has a real commercial base across the U.S., Europe, and Japan. In 2025, this is a specialist market, so adoption by pulmonologists and ID doctors matters more than broad primary-care reach. That means persistence on therapy and referral flow are the key growth levers, not mass-market promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e52-week evidence to support chronic use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed uses 52-week clinical and real-world evidence to keep ARIKAYCE in treatment plans as long as patients can tolerate it. In refractory MAC lung disease, durability matters more than a fast response; in CONVERT, culture conversion was 29% with ARIKAYCE plus guideline therapy vs 9% with guideline therapy alone at 6 months. That long-horizon proof helps repeat prescribing and offsets treatment fatigue and drop-off.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 specialist groups: pulmonology and infectious disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed’s market penetration is built on pulmonologists and infectious-disease specialists, not broad primary care. That fit matters because NTM is rare, with U.S. prevalence often estimated at 13 to 20 cases per 100,000 people, and care is clustered in referral centers and specialty clinics. This focused model lets Insmed teach diagnosis, culture testing, and treatment sequencing where it can change prescribing fastest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess support to reduce abandonment at launch and refill\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsmed can widen market penetration by pairing patient support, reimbursement help, and specialty-pharmacy execution so the first prescription turns into a fill. In orphan lung disease, access friction often matters more than awareness; prior authorization and cost checks can stop a start even after diagnosis. The key revenue step is keeping patients past the first fill and through the 2nd or 3rd refill, because early drop-off kills lifetime value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-value NTM centers instead of broad promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, Insmed kept market penetration focused on the highest-yield NTM centers and key referrers, instead of broad, undifferentiated promotion. That fits a rare-disease model: a small number of centers can drive a large share of starts, so sales spend goes farther and productivity rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARIKAYCE Gains Ground in Specialist NTM Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Insmed’s market penetration for ARIKAYCE stayed concentrated in specialty NTM centers, where the U.S. refractory MAC market is small but high value. CONVERT showed 29% culture conversion at 6 months versus 9% on guideline therapy, and that evidence supports repeat use, refill persistence, and referral growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 data point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCONVERT culture conversion\u003c\/td\u003e\n\u003ctd\u003e29% vs 9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTM U.S. prevalence\u003c\/td\u003e\n\u003ctd\u003e13-20 per 100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary growth lever\u003c\/td\u003e\n\u003ctd\u003eSpecialist referral flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a concise Amsoff Matrix view of Insmed’s growth strategy across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Insmed Ansoff Matrix snapshot for quick pain-point relief and faster growth strategy alignment.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARIKAYCE across 3 commercial regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, ARIKAYCE gave Insmed a 3-region base: the U.S., Europe, and Japan, so the market-development job is now country-by-country execution, not a single-launch build. The key work is local access, national reimbursement, and physician education, because rare-disease uptake still depends on who can actually get paid for the drug and who knows to prescribe it.\u003c\/p\u003e\n\u003cp\u003eThis matters because ARIKAYCE is already approved across major commercial markets, but growth now comes from deeper penetration in each one, not new geography alone.\u003c\/p\u003e\n\u003cp\u003eThat makes ARIKAYCE a clear market-development move in the Ansoff Matrix: same product, broader regional reach, with each market needing its own payer and specialist push.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 mature ex-U.S. access systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurope and Japan are market development, not product change: Insmed is selling an existing therapy into two mature, rule-heavy access systems. ARIKAYCE was approved in Japan in 2018 and in the EU in 2020, but uptake still depends on country-by-country payer, formulary, and specialist buy-in in NTM. That makes ex-U.S. growth a coverage-and-education game, not a new-product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader NTM awareness beyond referral hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed is widening NTM awareness beyond elite referral hospitals to pull more patients into diagnosis. That matters because NTM lung disease is often missed for months, so each extra test and referral can add treated volume for ARIKAYCE without changing the label. The market is still early, so even modest gains in awareness can expand the addressable pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMore prescribers in community and regional settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInsmed's second growth lane is moving from a narrow specialist base into more community and regional pulmonology practices. That works because diagnosis may start outside a tertiary center, but treatment still stays under specialty oversight, so the same product can reach more prescribers without changing the core model. Broadening access in 2025 widens the addressable pool and can lift script volume fast if referral links stay tight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential expansion into additional NTM use cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInsmed can widen ARIKAYCE use by educating clinicians on additional NTM subtypes and harder refractory cases, not just MAC. NTM pulmonary disease still affects a small but growing pool, so even a small lift in diagnosed and treatable patients can move rare-disease revenue. The key is keeping ARIKAYCE top of mind as physicians see broader mycobacterial patterns in 2025 practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARIKAYCE Growth Now Hinges on Deeper Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, ARIKAYCE is already in 3 regions, so Insmed’s market development is about deeper access, not a new launch. Japan (2018) and the EU (2020) add scale, but growth still hinges on payer coverage, formulary wins, and specialist education. NTM uptake stays limited by diagnosis gaps, so more referrals can lift scripts fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003e2025 role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eDeeper penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU\u003c\/td\u003e\n\u003ctd\u003eAccess expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003eSpecialist uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eInsmed Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Insmed Amsoff Matrix analysis document you’ll receive upon purchase—no surprises, just the full professional version. The preview below is taken directly from the complete report, so what you see is what you get. Once purchased, the full Insmed Amsoff Matrix analysis becomes available immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrensocatib: 1,680 patients, 31 countries, 52 weeks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrensocatib is Insmed’s key next-product program because ASPEN brought Phase 3 scale: about 1,680 patients in 31 countries over 52 weeks, a rare breadth for a pulmonary drug. That size improves confidence in both efficacy and safety signals, which matters in regulatory review. It also helps payer scrutiny because the dataset is wider than the usual rare-disease package.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eASPEN hit 2 primary endpoints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eASPEN, the phase 3 trial of brensocatib, met both primary endpoints in non-cystic fibrosis bronchiectasis, giving Insmed a real basis for commercialization planning. That matters because it shows the asset can cut disease burden and improve clinically meaningful outcomes, not just move a lab marker.\u003c\/p\u003e\n\u003cp\u003eFor Insmed, this is the clearest step toward a second pulmonary franchise alongside ARIKAYCE, and it strengthens the product development case for brensocatib.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTPIP: once-daily inhaled prostacyclin pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed is advancing TPIP, a once-daily inhaled treprostinil program for pulmonary hypertension, as a distinct growth path from ARIKAYCE. \u003c\/p\u003e\n\u003cp\u003eThat makes TPIP a true next-generation product bet, because it targets a different disease area and a higher-frequency chronic inhalation use case. \u003c\/p\u003e\n\u003cp\u003eIf TPIP succeeds, Insmed could compete in a market where current inhaled prostacyclin therapy is typically used multiple times per day.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 pipeline pillars beyond ARIKAYCE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsmed is no longer tied to ARIKAYCE alone. Brensocatib and TPIP give it two separate development paths, so the business has more shots on goal and a better base for revenue after the NTM franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D aimed at inflammation and vascular disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, Insmed’s R\u0026amp;D spans neutrophil-driven airway inflammation and pulmonary vascular disease, so the pipeline is no longer tied to one disease biology. That mix lowers concentration risk if one late-stage program hits a regulatory delay or slower launch. It also gives Insmed more shots on goal across two distinct clinical pathways. That is the core product-development upside in its Ansoff growth path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed’s 2025 Pipeline Gains Momentum as Brensocatib Clears ASPEN\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed’s product development in 2025 is centered on brensocatib and TPIP, reducing dependence on ARIKAYCE alone. ASPEN enrolled about 1,680 patients across 31 countries for 52 weeks and met both primary endpoints, which strengthens the case for launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrensocatib\u003c\/td\u003e\n\u003ctd\u003eASPEN: 1,680 patients, 31 countries, 52 weeks, 2 endpoints met\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTPIP\u003c\/td\u003e\n\u003ctd\u003eOnce-daily inhaled treprostinil\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom 1 marketed drug to 3 future growth pillars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed is moving from one marketed drug, ARIKAYCE, to 3 growth pillars: the current commercial base, brensocatib, and TPIP. That is a clear shift from single-product risk to a multi-asset biopharma model. Brensocatib and TPIP also target different diseases and buying centers, so each can grow on a separate market path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBronchiectasis opens a much larger patient pool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrensocatib moves Insmed into non-cystic fibrosis bronchiectasis, a pool far bigger than refractory MAC. The U.S. addressable base is commonly estimated at about 500,000 patients, with more than 5 million globally, versus the much smaller MAC niche. That scale can support a second specialty sales force and a broader, more durable revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePulmonary hypertension adds a separate commercial market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePulmonary hypertension gives Insmed a separate commercial lane from infectious bronchiectasis and NTM, so PIP can open a new market instead of just widening ARIKAYCE. That matters because pulmonary hypertension is managed by specialist centers, often with chronic therapy, and reimbursement is usually handled differently from an inhaled anti-infective.\u003c\/p\u003e\n\u003cp\u003eIn the U.S., pulmonary hypertension affects about 50,000 to 100,000 people, which makes it a real but distinct orphan-style market. If TPIP works, Insmed can cut its reliance on one respiratory segment and build a second growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 distinct science platforms lower single-asset risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInsmed’s diversification is real because it is building on 2 distinct science platforms: neutrophil biology for brensocatib and inhaled prostacyclin for TPIP. Those programs attack different disease drivers, so one clinical miss is less likely to sink the whole pipeline. They also sit in different prescribing settings, which spreads commercial risk.\u003c\/p\u003e\n\u003cp\u003eThat matters in 2025 because Insmed is not just adding products; it is reducing single-asset dependence while building two separate launch paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonger-term revenue mix can broaden after 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIf Insmed executes, 2026-plus should shift revenue from one commercial product toward multiple launch and growth curves. That matters because ARIKAYCE still drives most sales, while late-2020s value could come from 1 mature asset plus 2 emerging assets. A wider mix would reduce reliance on one price point and make cash flow less exposed to competition or reimbursement pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed’s next growth engine: brensocatib and TPIP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed’s diversification strategy shifts it beyond ARIKAYCE into two new markets: brensocatib for non-cystic fibrosis bronchiectasis and TPIP for pulmonary hypertension. That cuts single-product risk and opens separate launch paths. In 2025, the U.S. bronchiectasis pool is about 500,000 patients, while pulmonary hypertension affects 50,000 to 100,000 people in the U.S.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003e2025 relevance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ebrensocatib\u003c\/td\u003e\n\u003ctd\u003eBronchiectasis\u003c\/td\u003e\n\u003ctd\u003e~500,000 U.S. patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTPIP\u003c\/td\u003e\n\u003ctd\u003ePulmonary hypertension\u003c\/td\u003e\n\u003ctd\u003e50,000 to 100,000 U.S. patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53648119693654,"sku":"insmed-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/insmed-ansoff-analysis.webp?v=1778887989","url":"https:\/\/balancedscorecardexamples.com\/products\/insmed-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}